Scientific Opinion on the safety of “citicoline” as a Novel Food ingredient

EFSA Journal

Volumn 11, Issue 10, 2013, Pages

[No Author Info available]

Author keywords

CDP choline; citicoline; ingredient; novel food

Indexed keywords

EID: 85043701017     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2013.3421     Document Type: Article

References (43)

1. Adibhatla RM and Hatcher JF, 2005. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochemical Research, 30, 15–23.
2. Aguilar J, Gimenez R, Bachs O, Enrich C and Agut J, 1983. Cerebral subcellular distribution of CDP-choline and/or its metabolites after oral administration of methyl-14C CDP-choline. Arzneimittel-Forschung, 33, 1051–1053.
3. Agut J, Font E, Sacristan A and Ortiz JA, 1983. Bioavailability of methyl-14C CDP-choline by oral route. Arzneimittel-Forschung, 33, 1045–1047.
4. Agut J, Ortiz J and Wurtman R, 2000. Cytidine (5′)diphosphocholine modulates dopamine K(+)- evoked release in striatum measured by microdialysis. Annals of the New York Academy of Sciences, 920, 332–335.
5. Alvarez XA, Laredo M, Corzo D, Fernandez-Novoa L, Mouzo R, Perea JE, Daniele D and Cacabelos R, 1997. Citicoline improves memory performance in elderly subjects. Methods and Findings in Experimental and Clinical Pharmacology, 19, 201–210.
6. Alvarez XA, Mouzo R, Pichel V, Perez P, Laredo M, Fernandez-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R and Cacabelos R, 1999. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods and Findings in Experimental and Clinical Pharmacology, 21, 633–644.
7. Bidulescu A, Chambless LE, Siega-Riz AM, Zeisel SH and Heiss G, 2007. Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. BMC Cardiovascular Disorders, 7, 20.
8. Cho HJ and Kim YJ, 2009. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods and Findings in Experimental and Clinical Pharmacology, 31, 171–176.
9. Clark WM, Warach SJ, Pettigrew LC, Gammans RE and Sabounjian LA, 1997. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology, 49, 671–678.
10. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA and Gammans RE, 1999. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke, 30, 2592–2597.
11. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE and Citicoline Stroke Study G, 2001. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology, 57, 1595–1602.
12. Cotroneo AM, Castagna A, Putignano S, Lacava R, Fanto F, Monteleone F, Rocca F, Malara A and Gareri P, 2013. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clinical Interventions in Aging, 8, 131–137.
13. D'Orlando KJ and Sandage BW, Jr., 1995. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurological Research, 17, 281–284.
14. Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, Lopez S, Cobo E, Warach S, Sherman D, Clark WM and Lozano R, 2002. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke, 33, 2850–2857.
15. Davalos A, Alvarez-Sabin J, Castillo J, Diez-Tejedor E, Ferro J, Martinez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ and International Citicoline Trial on acUte Stroke trial i, 2012. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, 380, 349–357.
16. Dinsdale JR, Griffiths GK, Castello J, Maddock J, Ortiz JA and Aylward M, 1983a. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittel-Forschung, 33, 1061–1065.
17. Dinsdale JR, Griffiths GK, Rowlands C, Castello J, Ortiz JA, Maddock J and Aylward M, 1983b. Pharmacokinetics of 14C CDP-choline. Arzneimittel-Forschung, 33, 1066–1070.
18. Doerfler W and Schubbert R, 1998. Uptake of foreign DNA from the environment: the gastrointestinal tract and the placenta as portals of entry. Wiener Klinische Wochenschrift, 110, 40–44.
19. EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the Tolerable Upper Intake Level of Phosphorus (Request no EFSA-Q-2003-018, adopted on 1 July 2005, European Food Safety Authority). The EFSA Journal 2005, 209, 1–10.
20. EFSA (European Food Safety Authority), 2009. Scientific Opinion of the Panel on Food Additives and Nutrient Sources added to Food (ANS) on orotic acid salts as sources of orotic acid and various minerals added for nutritional purposes to food supplements, following a request from the European Commission (Question No EFSA-Q-2005-135, EFSA-Q-2005-139, EFSA-Q-2005-148, EFSA-Q-2005-163, EFSA-Q-2006-232, EFSA-Q-2006-233 [etc.], adopted on 7 July 2009 by European Food Safety Authority). The EFSA Journal 2009, 1187, 1–25.
21. Gimenez R, Raich J and Aguilar J, 1991. Changes in brain striatum dopamine and acetylcholine receptors induced by chronic CDP-choline treatment of aging mice. British Journal of Pharmacology, 104, 575–578.
22. IOM (Institute of Medicine), 1998. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B(6), Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. A Report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients, Food and Nutrition Board, Institute of Medicine (IOM). 390–422.
23. JPC, 1997. Citicoline. In: The Japanese Pharmaceutical Codex. Yakugyo Jiho Co., Ltd., Tokyo, Japan, 311–313.
24. Kanabayashi T, Shiota K, Mizuno M, Isaka H and Hoshino K, 1980. Toxicological studies on citicoline. acute and subacute toxicity study in mice and rats. Oyo Yakuri. Pharmacometrics, 20, 109–126.
25. Killgore WD, Ross AJ, Kamiya T, Kawada Y, Renshaw PF and Yurgelun-Todd DA, 2010. Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods. International Journal of Eating Disorders, 43, 6–13.
26. Kyowa Safety Research Laboratories, 1993. Mutagenicity Studies of CTCF and CTCL: Final Report. Unpublished study report. Kyowa Safety Research Laboratories, Tokyo, Japan. pp. 12.
27. Liao KY, Wu TC, Huang CF, Lin CC, Huang IF and Wu L, 2011. Profile of nucleotides and nucleosides in Taiwanese human milk. Pediatr Neonatol, 52, 93–97.
28. Liebl W, 2005. Cornyebacterium taxonomy. In: Cornyebacterium Glutamicum. Eds Eggeling L, Bott M. CRC Press Taylor & Francis Group, Boca Raton, FL, 9–36.
29. Lopez GCI, Agut J, Von Borstel R and Wurtman RJ, 1987. Metabolism of cytidine (5?)- diphosphocholine (cdp-choline) following oral and intravenous administration to the human and the rat. Neurochemistry International, 11, 293–297.
30. Lozano F, 1983. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittel-Forschung [Drug Research], 33, 1073–1080.
31. McGlade E, Locatelli A, Hardy J, Kamiya T, Morita M, Morishita K, Sugimura Y and Yurgelun-Todd D, 2012. Improved attentional performance following citicoline administration in healthy adult women. Food and Nutrition Sciences, 3, 769–773.
32. Rejdak R, Toczolowski J, Solski J, Duma D and Grieb P, 2002. Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Research, 34, 146–149.
33. Romero A, Serratosa J, Sacristan A and Ortiz JA, 1983a. High-resolution autoradiography in mouse brain 24 h after radiolabelled CDP-choline administration. Arzneimittel-Forschung, 33, 1056–1058.
34. Romero A, Serratosa J, Sacristan A and Ortiz JA, 1983b. High-resolution autoradiography in mouse brain and cerebellum 10 days after radiolabelled CDP-choline administration. Arzneimittel-Forschung, 33, 1058–1060.
35. Romero A, Serratosa J, Sacristan A and Ortiz JA, 1983c. Low-resolution autoradiography in rat brain after administering labelled CDP-choline. Arzneimittel-Forschung, 33, 1054–1056.
36. Schauss A, Financsek I, Somfai-Relle S, Varga T, Szucs Z, Glavits R, Kover A and Bara I, 2004. Final Report. Subchronic (90-day) oral toxicity study of citicoline - free base in rats. Study code: PCDL-0308. Pharmaceutical Control and Development Laboratory Co. Ltd. Budapest. Unpublished study report, 69 pp.
37. Schauss AG, Somfai-Relle S, Financsek I, Glavits R, Parent SC, Endres JR, Varga T, Szucs Z and Clewell A, 2009. Single- and repeated-dose oral toxicity studies of citicoline free-base (choline cytidine 5′-pyrophosphate) in Sprague-Dawley rats. International Journal of Toxicology, 28, 479–487.
38. Secades JJ and Frontera G, 1995. CDP-choline: pharmacological and clinical review. Methods and Findings in Experimental and Clinical Pharmacology, 17 Suppl B, 1–54.
39. Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, Renshaw PF and Yurgelun-Todd DA, 2008. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR in Biomedicine, 21, 1066–1075.
40. Spiers PA, Myers D, Hochanadel GS, Lieberman HR and Wurtman RJ, 1996. Citicoline improves verbal memory in aging. Archives of Neurology, 53, 441–448.
41. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U and Gammans R, 2000. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Annals of Neurology, 48, 713–722.
42. Wurtman RJ, Regan M, Ulus I and Yu L, 2000. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochemical Pharmacology, 60, 989–992.
43. Zeisel SH, Mar MH, Howe JC and Holden JM, 2003. Concentrations of choline-containing compounds and betaine in common foods. Journal of Nutrition, 133, 1302–1307.